Vnitr Lek 2025, 71(5):326-328
How to properly interpret lipid profile results
- Oddělení klinické biochemie, Fakultní nemocnice u sv. Anny v Brně
- II. interní klinika, Lékařská fakulta MU, Brno
The lipid profile usually includes total cholesterol, triglycerides, LDL-cholesterol, HDL-cholesterol and calculation of non-HDL-cholesterol. It is optimal to evaluate the results in their mutual context, not in isolation as a single parameter. The concentration of triglycerides and total cholesterol is important for assessing whether atherogenic dyslipidemia is present, whether the LDL-cholesterol result can be relied on, and whether non-HDL-cholesterol can be used to estimate risk according to the SCORE2 tables. Lipoprotein(a) and apolipoprotein B can be used to specify the risk. It is also appropriate to take into account the reliability of blood lipid measurements, since the measurement of LDL-cholesterol, HDL-cholesterol and lipoprotein(a) is not standardized between laboratories.
Keywords: cholesterol, triacylglycerols, apolipoprotein B, lipoprotein(a).
Accepted: August 25, 2025; Published: September 18, 2025 Show citation
References
- Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-3337.
Go to original source...
Go to PubMed...
- SÚKL. Rozhodnutí o změně podmínek úhrady léčivého přípravku Repatha 140MG INJ SOL 2x1ML, správní řízení sp. zn. SUKLS29290/2019, č. jedn. sukl4530/2021 ze dne 7. 1. 2021. SÚKL; 2021.
- SÚKL. Rozhodnutí o změně podmínek úhrady léčivého přípravku Praluent 75 mg, F-CAU-003-02R/31. 08. 2018, Sp. zn. SUKLS85942/2019, č. jedn. sukl209748/2020, ze dne 20. 8. 2020. SÚKL; 2020.
- Martin SS, Giugliano RP, Murphy SA, et al. Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial. JAMA Cardiol. 2018;3:749-753.
Go to original source...
Go to PubMed...
- Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia. JAMA Cardiol. 2020;5:540-548.
Go to original source...
Go to PubMed...
- Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
Go to original source...
- Miller WG, Myers GL, Sakurabayashi I, et al. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem. 2010;56:977-986.
Go to original source...
Go to PubMed...
- Contois JH, Warnick GR, Sniderman AD. Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. J Clin Lipidol. 2011;5:264-272.
Go to original source...
Go to PubMed...
- Nordestgaard BG, Langlois MR, Langsted A, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46-61.
Go to original source...
Go to PubMed...
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41:111-188.
Go to original source...
Go to PubMed...
- Langlois MR, Descamps OS, van der Laarse A, et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. Atherosclerosis. 2014;233:83-90.
Go to original source...
Go to PubMed...
- Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2007;28:2375-2414.
Go to original source...
Go to PubMed...
- Ko DT, Alter DA, Guo H, et al. High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. J Am Coll Cardiol. 2016;68:2073-2083.
Go to original source...
Go to PubMed...
- Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J. 2017;38:2478-2486.
Go to original source...
Go to PubMed...
- Doggrell SA. What have we learnt from the clinical outcomes trials with the cetrapibs? Curr Opin Lipidol. 2018;29:327-332.
Go to original source...
Go to PubMed...
- Marston NA, Giugliano RP, Im K, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019;140:1308-1317.
Go to original source...
Go to PubMed...
- Santos-Baez LS, Ginsberg HN. Hypertriglyceridemia-Causes, Significance, and Approaches to Therapy. Front Endocrinol (Lausanne). 2020;11:616.
Go to original source...
Go to PubMed...
- Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384:626-635.
Go to original source...
Go to PubMed...
- Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43:3925-3946.
Go to original source...
Go to PubMed...
- Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4. J Am Coll Cardiol. 2021;77:1576-1589.
Go to original source...
Go to PubMed...
- Ruhaak LR, Cobbaert CM. Quantifying apolipoprotein(a) in the era of proteoforms and precision medicine. Clin Chim Acta. 2020;511:260-268.
Go to original source...
Go to PubMed...